"Safe haven" emerges after the cooling of the AI trading theme: Bank of America endorses $450 target price + value rotation ignites UnitedHealth Group Incorporated (UNH.US) counterattack trajectory.

After five consecutive trading days of decline in the stock price, the American health insurance giant UnitedHealth Group Incorporated (UNH.US) saw its stock price rise by over 5% on Thursday as the leaders of the AI computing industry chain collectively rebounded. Bank of America Corp recently upgraded its rating on this managed health giant from "neutral" to "buy" and significantly raised its target price from $420 to $450. The core reasons behind this move include strong second-quarter earnings prospects and institutional funds shifting focus from AI-related tech stocks to undervalued healthcare stocks amidst rising 10-year Treasury bond yields. The trajectory of UnitedHealth Group Incorporated's current stock price can be seen as being in a strong phase of valuation recovery and defensive asset repricing. On one hand, the cooling of healthcare utilization rates and improvement in risk-return expectations for managed care organizations (MCOs) have led top Wall Street institutions such as Bank of America Corp and Morgan Stanley to raise their target prices, thus providing a strong fundamental catalyst for the company's stock price. On the other hand, the pullback of AI-related tech stocks on Thursday, especially in AI semiconductor stocks like Broadcom Inc., ARM, and Micron Technology, led to a flow of risk-off funds towards healthcare and financial sectors, amplifying the relative performance of UnitedHealth Group Incorporated's stock compared to the S&P 500 and tech stock indices. In conclusion, Thursday's surge in UnitedHealth Group Incorporated's stock price is not only driven by the company's strengthening fundamentals, but also by a rotation of market style from crowded AI trading themes towards undervalued defensive leaders. Investment firms optimistic about the prospects of UnitedHealth Group Incorporated believe that if the company's second-quarter financial performance validates the continued decline in healthcare utilization rates, successful margin recovery, and no further deterioration in legal/regulatory risks, the stock price may continue its recovery trend and potentially form a strong upward wave. After a five-day decline, UnitedHealth Group Incorporated receives endorsement from Wall Street giants with a target price of $450 Senior analyst Kevin Fischbeck from Bank of America Corp cited a trend tracking indicator developed exclusively by Bank of America Corp, stating that the outstanding performance of the company in the first quarter was not just a result of a combination of a weak flu season and storm effects. These factors significantly led to a decrease in healthcare system utilization and boosted UnitedHealth Group Incorporated's overall profits. In other words, a weak flu season means lower demand for doctor visits, hospitalizations, medications, and emergencies compared to normal years; while stormy weather may cause some patients in certain areas to delay outpatient visits, surgeries, tests, or non-emergency medical services. Since health insurance companies have to foot the bill for insured individuals' medical expenses, a decrease in healthcare utilization leads to lower costs, improving the profit margin in the short term. The analysts at Morgan Stanley believe that industry performance in the first quarter was partially affected by delays in care due to the weak flu season and weather effects, but markets are still watching to see if this cost improvement is sustainable. However, Bank of America Corp analyst Fischbeck believes that this low healthcare utilization may not be just a short-term coincidence caused by weather and the flu, but a substantive improvement in healthcare cost trends. If it were only due to the weak flu season and storms, the demand for healthcare in the second quarter might bounce back, making profit improvement unsustainable. But BofA's trend tracker shows that healthcare utilization rates in April and May are still low, so he believes the prospects for second-quarter earnings are more favorable and has upgraded the stock rating for UnitedHealth Group Incorporated to "buy." Fischbeck wrote, "Improvements in healthcare cost trends and supportive recent data points have created favorable conditions for the second-quarter earnings trajectory, providing an attractive risk/reward." Therefore, he raised Bank of America Corp's target price for the stock from $420 to $450. In comparison, as of Thursday's closing on the stock market, UnitedHealth Group Incorporated's stock rose by 5.16% to $396.47, indicating a broader upside potential, according to Bank of America Corp. He added, "The latest multiple data points make it harder for investors to believe that the strong performance in the first quarter was more of a function of the weak flu season and storms." He noted that as there is actual evidence showing that healthcare utilization rates in April and May are still low, Bank of America Corp is more bullish on the overall sentiment towards managed care organizations (MCO) as they enter the second quarter. The analyst also added that if the current trend continues, given UnitedHealth Group Incorporated's key status in the stock market earnings season, the company is likely to lead a collective rise in stock prices among its MCO peers. This medical insurance giant based in Minnesota is typically the first managed care company/organization to report its financial data for the second quarter of 2026, expected to be announced in the middle to late next month. AITrend cooling shows a significant correction, as value and defensive stock rotation sparks UnitedHealth Group Incorporated counterattack trend Undoubtedly, the current trajectory of UnitedHealth Group Incorporated's stock price is in a strong upward phase of valuation recovery and repricing of value/defensive assets. Bank of America Corp recently upgraded its rating on this managed healthcare giant from "neutral" to "buy" and raised its target price to $450, with core reasons including strong prospects for second-quarter earnings and recent institutional profit-taking in popular AI tech stocks, combined with the rising 10-year Treasury bond yields that could reallocate funds to undervalued healthcare stocks. Thursday's surge in UnitedHealth Group Incorporated's stock price is not only driven by the company's strengthening fundamentals but also by the global stock market style rotation from crowded AI trading themes towards undervalued defensive leaders. With Broadcom Inc. announcing that its growth outlook in AI semiconductor industry falls short of Wall Street's expectations, there has been a noticeable cooling in the AI computing industry chain investment frenzy, sparking a rotation of funds towards value and defensive stocks, igniting UnitedHealth Group Incorporated's counterattack trend. Several analysts recently pointed out that the Nikkei 225, Nasdaq 100, Philadelphia Semiconductor Index, and South Korea's Kospi Composite Index have seen a too rapid rise in stock numbers, causing some market participants to become cautious and lock in profits after half a year, as concerns arose surrounding the global stock market AI investment frenzy. Pelham Smithers, Managing Director of Pelham Smithers Associates, said, "People are increasingly viewing AI investments as an AI bubble, and we predict that about 70% of the rise in the Japanese stock market in 2026 comes from tech stocks related to the AI ecosystem." As market caution grows, some global investors are looking to withdraw from Japan and South Korea and invest in markets like Europe, where AI influence and weight are less dominant. UnitedHealth Group Incorporated has had a lackluster performance over the past year mainly due to experiencing rare "resonating multiple negative effects" for a managed healthcare leader, such as significantly higher-than-expected Medicare Advantage medical cost trends, rising reimbursement pressure, a substantial cut in profit expectations for 2025, pressure on the value medical business of Optum Health, fallout from the Change Healthcare cyberattack, CEO changes, and increased scrutiny by the US Department of Justice on Medicare business. Prior news of a criminal investigation by the Department of Justice caused UnitedHealth Group Incorporated to drop nearly 13% in a single day, erasing over $300 billion in market value since its last all-time high. Thursday's jump in UnitedHealth Group Incorporated's stock price seems to be driven by expectations of healthcare cost improvements, Wall Street's rating upgrade, and the cooling of crowded AI tech trades, particularly as the core trading logic for UnitedHealth Group Incorporated's stock has shifted from being endorsed by Warren Buffett's Berkshire Hathaway to factors like the turning point in healthcare costs, margin recovery, and repricing of defensive leaders. If second-quarter financial results confirm the continued decline in healthcare utilization rates, successful margin recovery, and no further deterioration in legal/regulatory risks, the stock price may continue its recovery trend and even form a strong phase of the main uptrend; however, if healthcare costs rise again, Medicare Advantage regulatory pressures increase, or Optum Health fails to recover as expected, this upward trend may be only a short-term rebound from being oversold, ignited by a wave of value stock counterattack and moderate short-covering.